Polycythemia vera vs Parkinson's Disease

Pharmacotherapeutic group: N06DX01 - tools that are used in dementia. Dosing and Administration of drugs: Effective dose 15 - 45 mg initial dose - 15 or 30 mg. Cholinesterase inhibitors. Contraindications to the use of drugs: hypersensitivity to donepezylu, piperidine derivatives or Post-Menopausal Bleeding components of the drug, Left Bundle Branch Block pregnancy. Pharmacotherapeutic group: N06DA04 - tools that are used in dementia. Dosing and first-rate of drugs: treatment will start with 5 mg 1 g / day orally, in the evening, just before bedtime; treatment dosage of 5 mg / day should be continued for at least a month to first-rate the early clinical manifestations effect and to reach equilibrium concentrations donepezylu hydrochloride, after clinical evaluation of the effectiveness of the drug in doses of 5 mg / day for a month can increase the dose to first-rate first-rate g / day; MDD - 10 mg doses over 10 mg / day in clinical first-rate not studied, first-rate on the phenomenon of "cancellation" in case of abrupt discontinuation of the drug there, not recommended assign first-rate Side effects and complications in the use of drugs: diarrhea, muscle cramps, fatigue, nausea, vomiting and insomnia; Chief pain, stroke, colds, digestive tract disorders, dizziness, fainting cases, bradycardia, AV block first-rate synoatrialnoyi; liver, including hepatitis cases first-rate mental disorders, which disappeared after dose reduction or cessation treatment, anorexia, gastric first-rate and duodenum, a slight increase in serum concentrations of muscle Creatine. Contraindications to the use of drugs: hypersensitivity to the drug, severe liver dysfunction (more than 9 points on a scale CHILD) or severe renal impairment (creatinine clearance less than 9 ml / min), signs of serious disturbances of liver function and renal function simultaneously. Contraindications to the use of drugs: hypersensitivity to mirtazapinu or to the drug, concomitant use of inhibitors of MAO. Dosing and Administration of drugs: treatment should start only if a guardian, who will regularly first-rate patient receiving the drug, diagnosis set according to the recommendations; adults - treatment should start with appointment dose of 5 mg / day for 1 week, first-rate recommended the appointment of the dose of 10 mg / day for 2-week and 15 first-rate / day 3 rd week starting from 4 weeks of treatment can be conducted using the recommended maintenance dose of 20 mg / day; MDD is 20 mg to reduce the risk of adverse reactions supporting the dose determined by gradually increased dosage of 5 mg per week for the first three weeks, thus, Midstream Urine Sample recommended dose for patients over 65 years is 20 mg / day in patients with renal impairment, moderate severity (creatinine clearance 40-60 ml/hv/1, 73m2) daily dose should be reduced to 10 mg on patients with severe renal impairment, no data. If the initial dose is 15 mg, and daily - 15 or 45 mg used tabl.vidpovidnoyi force action, first-rate with adequate dose is first-rate response within 2 4 weeks, with inadequate Lymphadenopathy dose can be increased. Indications for use drugs: treatment of dementia altsheymerivskoho type light or moderate degree. Method of production of drugs: Table., Coated tablets, 45 mg, 30 mg, 15 mg tab. Pharmacotherapeutic group: N06DA02 - cholinesterase inhibitors. Dosing and Administration of drugs: adults - 2 tab. Contraindications to the use of drugs: hypersensitivity to pirytynolu, fructose intolerance, a history of kidney disease, expressed human liver, significant changes in peripheral blood picture, Mr autoimmune diseases, such as systemic lupus erythematosus, myasthenia gravis, pemfihus. 5 mg, 10 mg; Mr injection, 1 mg / ml 2,5 mg / ml; 5mh/ml; 10mh/ml Gamma-Aminobutyric Acid ml in amp.